Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

January 18, 2019

ADC Therapeutics announces first patient dosed in Phase I clinical trial of ADCT-601 in advanced solid tumors

ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that the first patient has been dosed in its Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics and anti-tumor activity of ADCT-601 in patients with selected solid tumors that are locally advanced or metastatic.

ADC Therapeutics announces first patient dosed in Phase I clinical trial of ADCT-601 in advanced solid tumors